MedTrace Logo

A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria

NCT00282919 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2014-06-26

Study results available
· View outcomes & findings →

Summary

The treatment of symptomatic, uncomplicated malaria caused by P. falciparum in adults.

Conditions

  • Falciparum Malaria

Interventions

DRUG

Azithromycin plus chloroquine

dose of 2000 mg Azithromycin plus 600 mg chloroquine base

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Colombia
  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282919 on ClinicalTrials.gov